Evidence map›Paper›PMID 36689119›Full record

ReviewCurrent HIV/AIDS reports2023

Advances in HIV Research Using Mass Cytometry.

Ashley F George, Nadia R Roan

Abstract readReview
In one paragraph

Review in Current HIV/AIDS reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ashley F GeorgeGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID 0000-0002-1482-5244
Nadia R RoanGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, 94158, USA. nadia.roan@gladstone.ucsf.edu.ORCID 0000-0002-5464-1976

Funding

HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI PILLAI, SATISH KUMAR · 2017 to 2021
$8.5M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Multiomics characterization, induction, and elimination of the HIV gut reservoirR01DK131526 · NIDDK · J. DAVID GLADSTONE INSTITUTES · PI Nancie Marie Archin, Nadia R Roan · 2022 to 2026
$3.7M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
Single-cell Analysis of Glycomic and Proteomic Features of the HIV ReservoirR21AI170166 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, ROAN, NADIA R · 2022 to 2023
$530k
Characterizing ART-free NK cell-mediated control of HIV infection in people living with HIVR21AI172060 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI ROAN, NADIA R · 2022 to 2023
$520k
Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive HealthK99HD110319 · NICHD · J. DAVID GLADSTONE INSTITUTES · PI GEORGE, ASHLEY F · 2022 to 2023
$253k
NIAID NIH HHS P01 AI131374NIAID NIH HHS P01 AI169606NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI147777NIAID NIH HHS R21 AI170166NIAID NIH HHS R21 AI172060NIAID NIH HHS T32 AI007334NIAID NIH HHS UM1 AI164559NIAID NIH HHS UM1 AI164567NICHD NIH HHS K99 HD110319NIDDK NIH HHS R01 DK131526
6 · The paper itself

Abstract

purpose of reviewThis review describes how advances in CyTOF and high-dimensional analysis methods have furthered our understanding of HIV transmission, pathogenesis, persistence, and immunity. RECENT

findingsCyTOF has generated important insight on several aspects of HIV biology: (1) the differences between cells permissive to productive vs. latent HIV infection, and the HIV-induced remodeling of infected cells; (2) factors that contribute to the persistence of the long-term HIV reservoir, in both blood and tissues; and (3) the impact of HIV on the immune system, in the context of both uncontrolled and controlled infection. CyTOF and high-dimensional analysis tools have enabled in-depth assessment of specific host antigens remodeled by HIV, and have revealed insights into the features of HIV-infected cells enabling them to survive and persist, and of the immune cells that can respond to and potentially control HIV replication. CyTOF and other related high-dimensional phenotyping approaches remain powerful tools for translational research, and applied HIV to cohort studies can inform on mechanisms of HIV pathogenesis and persistence, and potentially identify biomarkers for viral eradication or control.

Indexed as

HIV InfectionsCD4-Positive T-LymphocytesHumansVirus LatencyVirus ReplicationCyTOFHIV-1NK cellsPP-SLIDET cellsViral remodeling

Identifiers

PMID36689119
PMCPMC9869313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.